Shiraz E-Medical Journal

Published by: Kowsar

Monitoring and Evaluation of Program Performance and Management Control System of Tuberculosis: A Ten-Year Cross-Sectional Study in Sistan and Baluchestan Province, Iran

Farhad Motamedizadeh 1 , Khalil Alimohammadzadeh 2 , 3 , * and Seyed Mojtaba Hosseini 4
Authors Information
1 North Tehran Branch, Islamic Azad University, Tehran, Iran
2 Department of Health Services Management, North Tehran Branch, Islamic Azad University, Tehran, Iran
3 Health Economics Policy Research Center, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
4 Scientific Composition of Health Services Management, North Tehran Branch, Islamic Azad University, Tehran, Iran
Article information
  • Shiraz E-Medical Journal: September 2018, 19 (9); e60497
  • Published Online: July 3, 2018
  • Article Type: Brief Report
  • Received: December 24, 2017
  • Revised: May 26, 2018
  • Accepted: May 31, 2018
  • DOI: 10.5812/semj.60497

To Cite: Motamedizadeh F, Alimohammadzadeh K, Hosseini S M. Monitoring and Evaluation of Program Performance and Management Control System of Tuberculosis: A Ten-Year Cross-Sectional Study in Sistan and Baluchestan Province, Iran, Shiraz E-Med J. 2018 ; 19(9):e60497. doi: 10.5812/semj.60497.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-95. doi: 10.1093/cid/ciw376. [PubMed: 27516382].
  • 2. Rendon A, Centis R, D'Ambrosio L, Migliori GB. WHO strategies for the management of drug-resistant tuberculosis. Arch Bronconeumol. 2017;53(3):95-7. doi: 10.1016/j.arbres.2016.07.015. [PubMed: 27717622].
  • 3. Falzon D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3). doi: 10.1183/13993003.02308-2016. [PubMed: 28331043]. [PubMed Central: PMC5399349].
  • 4. Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy. Immunol Lett. 2017;190:206-12. doi: 10.1016/j.imlet.2017.08.003. [PubMed: 28827021].
  • 5. Wu S, Roychowdhury I, Khan M. Evaluating the impact of healthcare provider training to improve tuberculosis management: a systematic review of methods and outcome indicators used. Int J Infect Dis. 2017;56:105-10. doi: 10.1016/j.ijid.2016.11.421. [PubMed: 27979785].
  • 6. Moosazade M, Jamshidi M, Amiresmaili M, Nezammahalleh A. A comparison of directly observed therapy and self-administered therapy strategies in treatment of pulmonary tuberculosis: A cohort study in north of Iran. Middle East J Sci Res. 2012;11(7):873-80.
  • 7. Takarinda KC, Harries AD, Nyathi B, Ngwenya M, Mutasa-Apollo T, Sandy C. Tuberculosis treatment delays and associated factors within the Zimbabwe national tuberculosis programme. BMC Public Health. 2015;15:29. doi: 10.1186/s12889-015-1437-7. [PubMed: 25631667]. [PubMed Central: PMC4314739].
  • 8. Jalalmanesh S, Darvishi M, Rahimi M, Akhlaghdoust M. Contamination of senior medical students’ cell phones by nosocomial infections: A survey in a university-affiliated hospital in Tehran. Shiraz E-Med J. 2017;18(4). e59938. doi: 10.5812/semj.43920.
  • 9. Dooley KE, Lahlou O, Ghali I, Knudsen J, Elmessaoudi MD, Cherkaoui I, et al. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Public Health. 2011;11:140. doi: 10.1186/1471-2458-11-140. [PubMed: 21356062]. [PubMed Central: PMC3053250].
  • 10. Atre SR, Murray MB. Management and control of multidrug-resistant tuberculosis (MDR-TB): Addressing policy needs for India. J Public Health Policy. 2016. doi: 10.1057/jphp.2016.14. [PubMed: 27153155].
  • 11. Olfatifar M, Hosseini SM, Parvin M. Spatiotemporal analysis of pulmonary tuberculosis in Hamadan province using population attributable risk. Iran J Epidemiol. 2017;13(1):22-9.
  • 12. Adineh HA, Motametdi B, Veisi M, Bagheri S. Risk factors of tuberculosis treatment failure in South-East of Iran. J Gorgan Univ Med Sci. 2014;16(2):50-6.
  • 13. Martin LER, Byrne AW, O’Keeffe J, Miller MA, Olea-Popelka FJ. Weather influences trapping success for tuberculosis management in European badgers (Meles meles). Europ J Wildlife Res. 2017;63(1):30. doi: 10.1007/s10344-017-1089-2.
  • 14. Namukwaya E, Nakwagala FN, Mulekya F, Mayanja-Kizza H, Mugerwa R. Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda. Afr Health Sci. 2011;11 Suppl 1:S105-11. [PubMed: 22135634]. [PubMed Central: PMC3220128].
  • 15. Panickar JR, Hoskyns W. Treatment failure in tuberculosis. Eur Respir J. 2007;29(3):561-4. doi: 10.1183/09031936.00092406. [PubMed: 17135229].
  • 16. de Vries G, van Hest R, Bakker M, Erkens C, van den Hof S, Meijer W, et al. Policy and practice of programmatic management of latent tuberculosis infection in The Netherlands. J Clin Tuberc Other Mycobact Dis. 2017;7:40-8. doi: 10.1016/j.jctube.2017.02.002.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments